Literature DB >> 21267563

Hepatocellular nodules in liver cirrhosis: state of the art CT evaluation (perfusion CT/volume helical shuttle scan/dual-energy CT, etc.).

Masahiro Okada1, Tonsok Kim, Takamichi Murakami.   

Abstract

The purpose of this article is to explain the role of advanced liver CT imaging, including perfusion CT, dual-energy CT, and volume helical shuttle (VHS) scanning, with regard to its clinical applications. Perfusion CT is a promising method for calculating hepatic blood flow and portal blood flow, including microcirculation, using a color-encoded display of parameters obtained from the liver time-density curve, with iodine contrast agent. Tumor angiogenesis and assessment of the response to antiangiogenesis treatment (e.g., Sorafenib) can be analyzed by perfusion CT of the liver. VHS scan has very high temporal resolution due to the reciprocating movement employed during scanning, enabling the acquisition of 24 scans of the whole liver in the arterial dominant phase during a 40-s breath hold, and a reduction in radiation dose. Dual-energy CT enables differentiation of materials and tissues based on their CT density values, using two different energy spectra. This method includes a low tube voltage CT technique that increases the contrast enhancement of vascular structures while simultaneously reducing radiation dose. Images obtained at the preferred settings of low tube voltage and high tube current, with dose reduction in the hepatic arterial phase, are useful for detecting hypervascular hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21267563     DOI: 10.1007/s00261-011-9684-2

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  21 in total

1.  Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging.

Authors:  Davide Ippolito; Cristina Capraro; Alessandra Casiraghi; Cristina Cestari; Sandro Sironi
Journal:  Eur Radiol       Date:  2011-11-16       Impact factor: 5.315

2.  Time-resolved computed tomography of the liver: retrospective, multi-phase image reconstruction derived from volumetric perfusion imaging.

Authors:  Michael A Fischer; Bertil Leidner; Nikolaos Kartalis; Anders Svensson; Peter Aspelin; Nils Albiin; Torkel B Brismar
Journal:  Eur Radiol       Date:  2013-08-31       Impact factor: 5.315

Review 3.  Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.

Authors:  Adam S Bodzin; Ronald W Busuttil
Journal:  World J Hepatol       Date:  2015-05-28

Review 4.  Abdominal perfusion computed tomography.

Authors:  Hayri Ogul; Ummugulsum Bayraktutan; Yesim Kizrak; Berhan Pirimoglu; Zeynep Yuceler; M Erdem Sagsoz; Omer Yilmaz; Bulent Aydinli; Gurkan Ozturk; Mecit Kantarci
Journal:  Eurasian J Med       Date:  2013-02

Review 5.  Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others.

Authors:  Mecit Kantarci; Berhan Pirimoglu
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 6.  How Can New Imaging Modalities Help in the Practice of Radiology?

Authors:  Berhan Pirimoglu; Recep Sade; Hayri Ogul; Mecit Kantarci; Suat Eren; Akın Levent
Journal:  Eurasian J Med       Date:  2016-10

Review 7.  Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Tiffany Hennedige; Sudhakar K Venkatesh
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 8.  Liver masses: a clinical, radiologic, and pathologic perspective.

Authors:  Sudhakar K Venkatesh; Vishal Chandan; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-18       Impact factor: 11.382

Review 9.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 10.  Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma.

Authors:  Jeong Min Lee; Jeong-Hee Yoon; Ijin Joo; Hyun Sik Woo
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.